I. Introduction
===============

In thyroid glands, there are two different types of endocrine thyroid cells, namely, follicular thyroid cells and parafollicular C cells, from both of which thyroid carcinomas are derived. There are several histological types and subtypes of thyroid carcinoma with different cellular origins, characteristics and prognoses. According to the most recent World Health Organization (WHO) classification of thyroid tumors published in 2004, follicular thyroid cell-derived tumors include papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC), and these follicular thyroid cell-derived carcinomas account for the majority of thyroid malignancies. This WHO classification of thyroid tumors included PDTC as a new diagnostic category \[[@B62]\]. Therefore, it may be noted that publications prior to this WHO classification might include misinterpretations on histological types of thyroid carcinoma. Parafollicular C cell-derived medullary thyroid cancer (MTC) accounts for a small proportion of thyroid malignancies. The primary molecular mechanism underlying MTC tumorigenesis is the aberrant activation of RET signaling \[[@B17], [@B75]\]. The aberrant activation of RET signaling is caused by RETmutations, which are not present in follicular thyroid cell-derived tumors \[[@B75]\].

PDTC and ATC have a very poor prognosis. In contrast to these malignant subtypes, PTC and FTC are collectively classified as differentiated thyroid carcinoma (DTC). PTC is a major differentiated subtype that has slow growing characteristics and a good prognosis. FTC is another differentiated subtype that, in contrast to PTC, has a greater tendency of distant metastasis to such organs as lung and bone. Clinical overview of follicular thyroid cell-derived carcinomas is summarized in Table [1](#T1){ref-type="table"}.

Despite the slowly progressive, low grade malignancy of DTC, about 10% of patients with PTC and 20--40% of patients with FTC die of the disease \[[@B79]\]. Most deaths result from poor control of local disease and distant metastases. The lung is the most common metastatic site of thyroid carcinoma, followed by the bone \[[@B11], [@B21], [@B45], [@B47]\]. Skull metastasis of thyroid carcinoma is rare, with a small number of reported cases \[[@B2]--[@B4], [@B6]--[@B8], [@B12], [@B19]--[@B24], [@B26]--[@B28], [@B30], [@B32]--[@B35], [@B38]--[@B40], [@B42], [@B44], [@B45], [@B49]--[@B51], [@B53], [@B54], [@B56], [@B57], [@B60], [@B63]--[@B65], [@B68]--[@B70], [@B73], [@B77], [@B78]\]. The largest series of skull metastasis from thyroid carcinoma reported a frequency of only 2.5% among 473 patients \[[@B45]\]. Moreover, skull base metastasis from DTC is even rarer, with only 28 reported cases, including 18 cases of skull base metastasis from FTC \[[@B6], [@B7], [@B24], [@B30], [@B39], [@B44], [@B45], [@B49], [@B50], [@B54], [@B56], [@B57], [@B60], [@B63], [@B69], [@B70], [@B78]\] and 10 cases from PTC \[[@B4], [@B12], [@B20], [@B23], [@B34], [@B38], [@B64], [@B65], [@B77]\] (Table [2](#T2){ref-type="table"}). In this review article, the clinicopathological and molecular histochemical features and treatment modalities of skull base metastasis of DTC, namely, FTC and PTC, are discussed with a review of literatures on molecular pathogenesis.

II. Clinical and Histopathological Features of Skull Base Metastasis from FTC and PTC
=====================================================================================

Mean age of patients with skull base metastasis from FTC was 54.6 years, ranging from 23 to 74 years, and that of those from PTC was 53.5 years, ranging from 35 to 73 years. Bone metastasis from thyroid carcinoma is often observed in the sixth and seventh decades of life \[[@B40]\]. Similarly, 10 out of 18 patients with skull base metastasis of FTC and 3 out of 10 those from PTC are in the sixth and seventh decades. Skull base metastasis of FTC shows female predominance (13 females and 5 males), and this female predominance is generally observed in thyroid carcinoma. Skull base metastasis of PTC shows equal gender predominance. Although PTC is more common than FTC, FTC is more prone to spread hematogenously, especially to the lungs and bone \[[@B43]\]. Thus, larger number of literatures concerning skull base metastasis is found in FTC compared with PTC. The metastatic lesion is usually hypervascular and osteolytic on radiological examination \[[@B26]\]. Bleeding is often profuse during surgical resection \[[@B45]\]. The most common symptom of skull base metastasis from FTC is cranial nerve dysfunction, which was observed in 16 of the 18 cases. Cranial nerve dysfunction was found in 7 of 10 cases of PTC. Bone destruction and local invasion to the surrounding soft tissues are common on radiological images, so that skull base metastasis from FTC and PTC is often mistaken as chordoma or chondrosarcoma \[[@B6], [@B56]\]. The period between initial diagnosis and skull base metastasis from FTC ranged from 0 to 18 years, with a mean of 3.9 years. The period between initial diagnosis and skull base metastasis from PTC ranged from 0 to 18 years, with a mean of 6.8 years. Skull base metastases were the initial symptom of FTC in 9 of the 19 reported cases and that of PTC in 2 of the 9 reported cases.

No histopathological features that could predict bone metastasis, particularly skull base metastasis, of DTC were found in the literatures. Similarly, no particular histological features that could distinguish between DTC metastasizing to the skull base and the other sites were found in the literatures. Prognostic difference between DTC with skull base metastasis and those with other bone metastases was not found in the literature review. Other cancers such as lung cancer might metastasize to the skull base. Immunohistochemical studies of thyroid transcription factor-1 (TTF-1) and thyroglobulin (TGB) are useful for distinguishing between thyroid carcinoma and lung adenocarcinoma \[[@B59]\]. TTF-1 is an immunohistochemical marker used to confirm pulmonary and thyroid carcinoma, while TGB is expressed by thyroid carcinoma \[[@B59]\]. Immunohistochemical studies of high molecular weight keratin (CK 19) are also useful for discrimination between benign thyroid tumors and thyroid carcinoma. Focal CK19 staining may be found in benign disease, but diffuse and strong positivity is characteristic of PTC \[[@B5]\].

The possibility of skull base metastasis should be considered in the clinical course of FTC and PTC, and the patient should be meticulously followed up. Noticeably, skull base metastases can be the initial clinical presentation of more than half of the reported cases of FTC in the presence of silent primary sites, which emphasizes the unpredictable nature of FTC.

III. Treatment of Skull Base Metastasis from FTC and PTC
========================================================

The treatment algorithm for primary thyroid carcinomas includes nearly total or total thyroidectomy, followed by oral administration of ^131^I and thyroid-stimulating hormone (TSH) suppression \[[@B68]\]. However, there is no clear consensus concerning the treatment of skull base metastasis from FTC and PTC because of the rarity of these lesions. Several thyroidologists have recommended, as the first-line therapy, complete excision of the thyroid gland with as many of the metastatic lesions as possible \[[@B22], [@B45]\]. Surgical debulking is hazardous in most cases of skull base metastasis because of the presence of vital structures and profuse bleeding. Therefore, the second option is internal irradiation with ^131^I if scintigraphy taken by the metastatic lesions \[[@B45]\]. External irradiation should be administered to cold lesions identified by ^131^I scintigraphy \[[@B45]\]. Chronic suppression of endogenous TSH should be induced by the administration of thyroid hormone to prevent tumor growth \[[@B56]\]. Measurement of circulating TGB may be useful for predicting the recurrence of the differentiated thyroid carcinoma during follow-up \[[@B71]\]. The calculation of TGB/(TSH × ^131^I uptake in 24 hr) ratio has prognostic value in the treatment including ^131^I ablation therapy.

Bisphosphonates have been used widely to control bone metastasis of solid tumors such as breast and prostate cancers. The use of bisphosphonates for bone metastasis of thyroid carcinoma has been reported in only 2 patients \[[@B39], [@B67]\]. Administration of zoledronic acid and alendronate sodium hydrate decreased urinary type I collagen N-telopeptide, which indicated the suppression of bone resorption. Such suppression of bone resorption by bisphosphonates may be beneficial for patients with skull base metastasis of FTC and PTC.

IV. Molecular Pathogenesis of FTC and PTC
=========================================

A variety of genetic alterations in thyroid tumors have been identified to have a fundamental role in their tumorigenesis. First noted is T1799A transverse point mutation of BRAF, which causes the expression of BRAF-V600E mutant protein and then evokes the constitutive activation of this serine/threonine kinase \[[@B9], [@B13], [@B29], [@B46], [@B61], [@B75], [@B76]\]. A multicenter study demonstrated a strong association of BRAFV600E with poor clinicopathological outcomes of PTC, namely, aggressive pathological features, increased recurrence, loss of radioiodine avidity and treatment failures \[[@B74]\]. The other types of BRAF mutation are also noted. BRAF-G468E and BRAF-K601E mutations were observed in our cases of FTC (Figs. [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

Second prevalent mutations in thyroid carcinoma are RAS mutations. There are three isoforms of RAS: HRAS, KRAS and NRAS, and NRASis predominantly mutated in thyroid tumors \[[@B75]\]. RAS is a classical dual activator of the MAPK and PI3K-AKT pathways, and in thyroid tumorigenesis, RAS mutations seem to preferentially activate the PI3K-AKT pathway \[[@B1], [@B36]\]. The common occurrence of RAS mutations in follicular thyroid adenoma (FTA) suggests that activated RAS may have a role in early follicular thyroid cell tumorigenesis. However, additional genetic alterations other than RAS mutation are apparently required to transform FTA into thyroid carcinoma. Another study suggests that concurrent KRAS mutant expression and *PTEN* deletion induced a rapid occurrence of aggressive FTC \[[@B41], [@B75]\].

Mutations or deletions of the tumor suppressor gene PTENare the classical genetic alterations that activate the PI3K-AKT pathway and are the genetic basis for follicular thyroid cell tumorigenesis in Cowden's syndrome \[[@B16]\]. Mutations of PIK3CA are also common in thyroid cancer, particularly FTC, PDTC and ATC \[[@B1], [@B14], [@B18], [@B36], [@B55], [@B58], [@B72], [@B75]\].

Some genes such as TRK-fused gene have important role in pathogenesis of thyroid papillary carcinoma \[[@B15], [@B37], [@B66]\]. TRK-fused gene is a fusion partner of the NTRK1 gene \[[@B15]\], which encodes a tyrosine kinase receptor for nerve growth factor \[[@B25], [@B31]\].

It has been shown that COX-2 is involved in the pathomechanisms of thyroid carcinomas and chronic thyroiditis \[[@B10], [@B48]\]. Omi *et al.* performed an immunohistochemical analysis for membrane-bound PGES-1 (mPGES-1) in surgically resected thyroid gland tissues including PTC \[[@B52]\]. They found the involvement of mPGES-1 in proliferation and differentiation of PTC as well as local invasion of PTC.

Other genetic and epigenetic alterations include mutations in TP53, β-catenin (CTNNB1), anaplastic lymphoma kinase (ALK) and isocitrate dehydrogenase 1 (IDH1), translocations (RET-PTC and paired box 8 (PAX8)-peroxisome proliferator-activated receptor-γ (PPARG)) and aberrant gene methylation \[[@B75]\]. Gene amplification, copy-number gain and gene translocation are also genetic mechanism in thyroid tumorigenesis \[[@B75]\]. Additionally, at the core of the molecular pathogenesis of thyroid carcinoma is the uncontrolled activity of various signalling pathways, including the MAPK, PI3K-AKT, nuclear factor-κB (NF-κB), RASSF1-mammalian STE20-like protein kinase 1 (MST1)-forkhead box O3 (FOXO3), WNT-β-catenin, hypoxia-inducible factor 1α (HIF1α) and TSH-TSH receptor (TSHR) pathways \[[@B75]\].

Molecular histochemical studies are useful for elucidating the histopathological features of thyroid carcinoma. These recent molecular findings may provide novel molecular-based treatment strategies for thyroid carcinoma.

V. Conclusion
=============

Skull base metastasis from FTC and PTC is a rare clinical entity, and may be the initial clinical presentation of FTC and PTC in the presence of silent primary sites. Larger number of literatures concerning skull base metastasis is found in FTC compared to PTC. The possibility of skull base metastasis from FTC and PTC should be considered in patients with the clinical symptoms of cranial nerve dysfunction and radiological findings of bone destruction. Molecular histochemical studies are useful for elucidating the histopathological features of thyroid carcinoma. Recent molecular findings may provide novel molecular-based treatment strategies for thyroid carcinoma.
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![**a:** CT scan reveals skull base tumor invading the right middle cranial fossa. **b:** Pathological examination confirms the tumor is FTC (Hematoxylin-eosin staining). **c:** BRAF-K601E mutation is observed in the tumor cell (arrow).](AHC13019f01){#F1}

![**a:** CT scan reveals skull base tumor invading the left pyramidal bone. **b:** Pathological examination confirms the tumor is FTC (Hematoxylin-eosin staining). **c:** BRAF-G468E mutation is observed in the tumor cell (arrow).](AHC13019f02){#F2}

###### 

Clinical overview of follicular thyroid cell-derived carcinomas

  Tumor type                                       Prevalence (% of thyroid carcinomas)   Characteristics                                                                                                                                                                                                            Subtypes
  ------------------------------------------------ -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  papillary thyroid carcinoma (PTC)                80--85                                 Well differentiated, with papillary architecture and characteristic nuclear features, such as enlargement, oval shape, elongation, overlapping and clearing, inclusions and grooves. Propensity for lymphatic metastasis   conventional PTC (CPTC), follicular-variant PTC (FVPTC), tall-cell PTC (TCPTC), a few rare variants
  follicular thyroid carcinoma (FTC)               10--15                                 Well differentiated, hypercellular, microfollicular patterns, lacking nuclear features of PTC. Propensity for metastasis via the blood stream                                                                              Hurthle cell thyroid carcinoma
  poorly differentiated thyroid carcinoma (PDTC)   5--10                                  Poorly differentiated, often overlapping with PTC and FTC. Intermediate aggressiveness between differentiated and undifferentiated thyroid carcinomas                                                                      
  anaplastic thyroid carcinoma (ATC)               2--3                                   Undifferentiated, admixture of spindle, pleomorphic giant and epithelioid cells, extremely invasive and metastatic, highly lethal, may occur *de novo* or derive from PTC, FTC or PDTC                                     

(modified from Ref. 75.)

###### 

Summary of reported cases with skull base metastasis from follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC)

  Author                                         Age   Sex   Histology   Location of metastasis                                                                                                    Period from initial diagnosis to metastasis (yrs)   symptoms                                                                      treatment
  ---------------------------------------------- ----- ----- ----------- ------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------
  Trunnell *et al.* (1949) \[Ref. [@B69]\]       42    F     FTC         sphenoid sinus                                                                                                            0                                                   blurred vision, blindness                                                     ^131^I
  Kistler and Pribram (1975) \[Ref. [@B30]\]     69    F     FTC         sella turcica, clivus                                                                                                     9                                                   blurred vision, oculomotor nerve palsy                                        surgery
  Song *et al.* (1981) \[Ref. [@B63]\]           23    M     FTC         petrous ridge                                                                                                             0                                                   persistent headache, one episode of consciousness loss                        surgery, ^131^I, TSH suppression
  Nagamine *et al.* (1985) \[Ref. [@B45]\]       65    F     FTC         skull base                                                                                                                0                                                   visual impairment, exophtalamos                                               surgery, ^131^I, external radiation
  Ober *et al.* (1987) \[Ref. [@B49]\]           63    F     FTC         clivus                                                                                                                    7                                                   six nerve palsy                                                               ^131^I
  Ruchti *et al.* (1987) \[Ref. [@B57]\]         71    F     FTC         clivus, sella turcica, sphenoid sinus, petrous bone                                                                       0                                                   multiple cranial nerve paralysis                                              none (autopsy case)
  Ochiai *et al.* (1992) \[Ref. [@B50]\]         62    F     FTC         sella turcica, clivus, cavernous sinus, sphenoid sinus                                                                    0                                                   retro-orbital pain, diplopia due to abducens and oculomotor nerve paralyses   surgery, ^131^I
  Casals *et al.* (1995) \[Ref. [@B6]\]          61    M     FTC         clivus                                                                                                                    0                                                   palatal hypomotility, and weakness of the facial and tongue muscles           surgery, ^131^I, TSH suppression
  Vargas *et al.* (1999) \[Ref. [@B70]\]         46    F     FTC         clivus, cavernous sinus, skull vault                                                                                      8                                                   hypopituitarism                                                               surgery, ^131^I, external radiation, TSH suppression
  Rosahl *et al.* (2000) \[Ref. [@B56]\]         50    F     FTC         clivus, petrous bone                                                                                                      0.5                                                 dysphagia, dysphonia, hypoglossal paralysis                                   surgery, ^131^I, TSH suppression
  Kachhara *et al.* (2001) \[Ref. [@B24]\]       50    F     FTC         petrous apex, cavernous sinus                                                                                             0                                                   5th, 6th, 7th, 8th nerve palsy                                                surgery, ^131^I, external radiation
  Chrisoulidou *et al.* (2004) \[Ref. [@B7]\]    60    M     FTC         sella turcica, cavernous sinus                                                                                            4.5                                                 diplopia, ptosis                                                              surgery, external radiation
  Simon *et al.* (2004) \[Ref. [@B60]\]          23    F     FTC         sella turcica, sphenoid sinus, clivus                                                                                     0                                                   diplopia                                                                      surgery, ^131^I
  Yilmazlar *et al.* (2004) \[Ref. [@B78]\]      43    M     FTC         cavernous sinus, sphenoid sinus                                                                                           1.8                                                 visual impairment, galactorrhea                                               surgery, ^131^I, TSH suppression
  Mydlarz *et al.* (2007) \[Ref. [@B44]\]        74    M     FTC         clivus, sphenoid sinus, petrous apex, cavernous sinus, infratemporal fossa                                                0                                                   blurred vision, abducens nerve palsy                                          surgery, TSH suppression, ^131^I
  Pelaz *et al.* (2009) \[Ref. [@B54]\]          61    F     FTC         infratemporal fossa                                                                                                       18                                                  hemifacial pain, tongue and facial dysesthesia, hearing loss                  surgery, ^131^I, TSH suppression
  Matsuno *et al.* (2010) \[Ref. [@B39]\]        58    F     FTC         temporal base, infratemporal fossa, cavernous sinus, sphenoid sinus, occipital bone, clivus, petrous bone                 7                                                   facial dysesthesia, hearing disturbance, paraparesis in lower extremities     external radiation, surgery, TSH suppresion, ^131^I
  Matsuno *et al.* (2010) \[Ref. [@B39]\]        71    F     FTC         petrous bone                                                                                                              14                                                  7th and 8th nerve dysfunction                                                 surgery, external radiation, TSH suppresion, ^131^I
  Johnson and Atkins (1965) \[Ref. [@B23]\]      56    F     PTC         sella turcica, sphenoid sinus                                                                                             6                                                   blurred vision, 3rd and 6th nerve palsy                                       TSH suppression, ^131^I
  Sziklas *et al.* (1985) \[Ref. [@B64]\]        44    F     PTC         midline skull base, sella turcica                                                                                         18                                                  panhypopituitarism                                                            surgery, ^131^I
  Freeman *et al.* (1996) \[Ref. [@B12]\]        50    M     PTC         skull base, sphenoid sinus                                                                                                0.25                                                facial pain, exophthalmos, Horner's syndrome                                  surgery, ^131^I, external radiation
  Masiukiewicz *et al.* (1999) \[Ref. [@B38]\]   56    M     PTC         sella turcica                                                                                                             5                                                   panhypopituitarism                                                            ^131^I
  Masiukiewicz *et al.* (1999) \[Ref. [@B38]\]   55    F     PTC         cavernous sinus, sella turcica                                                                                            14                                                  panhypopituitarism, blindness                                                 ^131^I
  Bell *et al.* (2001) \[Ref. [@B4]\]            35    F     PTC         sella turcica                                                                                                             8                                                   hemianopsia, diabetes insipidus, amenorrhea                                   surgery
  Takami *et al.* (2002) \[Ref. [@B65]\]         41    M     PTC         cavernous sinus                                                                                                           10                                                  diplopia, subarachnoid hemorrhage                                             surgery, gamma knife
  Yan *et al.* (2010) \[Ref. [@B77]\]            73    M     PTC         petrous bone, sphenoid sinus, sella floor, clivus, pterygoid plate, ethmoid sinus, infratemporal fossa, cavernous sinus   0                                                   visual impairment, diplopia, epistaxis                                        surgery, TSH suppression, ^131^I
  Hugh *et al.* (2011) \[Ref. [@B20]\]           64    F     PTC         petrous bone                                                                                                              0                                                   no symptoms                                                                   surgery, external radiation
  Kutluhan *et al.* (2012) \[Ref. [@B34]\]       61    M     PTC         temporooccipital bone                                                                                                     NA                                                  multiple cranial nerve paralysis                                              surgery, ^131^I, external radiation

M: male, F: female
